CN105143250A - 一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂 - Google Patents

一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂 Download PDF

Info

Publication number
CN105143250A
CN105143250A CN201380075612.0A CN201380075612A CN105143250A CN 105143250 A CN105143250 A CN 105143250A CN 201380075612 A CN201380075612 A CN 201380075612A CN 105143250 A CN105143250 A CN 105143250A
Authority
CN
China
Prior art keywords
protein
sequence
seq
polypeptide
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380075612.0A
Other languages
English (en)
Other versions
CN105143250B (zh
Inventor
王瑞
黄金
张伟
卢水秀
史孟君
王军亮
司武亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING PROSPEROUS BIOPHARM CO LTD
Original Assignee
BEIJING PROSPEROUS BIOPHARM CO LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING PROSPEROUS BIOPHARM CO LTD filed Critical BEIJING PROSPEROUS BIOPHARM CO LTD
Publication of CN105143250A publication Critical patent/CN105143250A/zh
Application granted granted Critical
Publication of CN105143250B publication Critical patent/CN105143250B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开了一种新型的蛋白模板用于生成非抗体类靶向结合分子。所述蛋白模板及其衍生的靶向结合分子可与多肽、蛋白或化学功能分子形成融合蛋白或蛋白偶联物。由此，后者可具备可调节的靶向性或半衰期性质，同时保留结构稳定性和功能分子原有的活性，在制药及分子诊断领域有广泛应用前景。本发明也公开了一系列的GLP-1受体激动剂融合蛋白，所述高分子包括GLP-1受体激动剂多肽和靶向肽。其中，靶向肽为人工改造后的、能够与血清白蛋白可逆性地结合的肽。所述高分子还可以在靶向肽和GLP-1受体激动剂多肽之间包括一个连接分子。这类高分子药剂能够保留GLP-1受体激动剂多肽的活性，同时具有更长的体内半衰期，在治疗糖尿病、肥胖症、神经退行性疾病等领域具有较好的前景。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380075612.0A 2013-05-10 2013-05-10 一种改造非抗体类蛋白产生结合分子的方法及其产品和一种长效glp-1受体激动剂 Active CN105143250B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/075460 WO2014179983A1 (zh) 2013-05-10 2013-05-10 一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂

Publications (2)

Publication Number Publication Date
CN105143250A true CN105143250A (zh) 2015-12-09
CN105143250B CN105143250B (zh) 2020-11-03

Family

ID=51866644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380075612.0A Active CN105143250B (zh) 2013-05-10 2013-05-10 一种改造非抗体类蛋白产生结合分子的方法及其产品和一种长效glp-1受体激动剂

Country Status (2)

Country Link
CN (1) CN105143250B (zh)
WO (1) WO2014179983A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112420124A (zh) * 2021-01-19 2021-02-26 腾讯科技（深圳）有限公司 一种数据处理方法、装置、计算机设备和存储介质

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
CN106110325A (zh) * 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN102775487A (zh) * 2012-06-07 2012-11-14 北京华金瑞清生物医药技术有限公司 一类人工靶向融合蛋白和蛋白偶联物及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN102775487A (zh) * 2012-06-07 2012-11-14 北京华金瑞清生物医药技术有限公司 一类人工靶向融合蛋白和蛋白偶联物及其制备方法和应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LIU Z 等: "ChainA，Structural Basis For Recognition Of The Intron Branch Site RNA By Slicing Factor 1. PDB: 1K1G_A", 《PDB数据库》 *
LOPPNAU,P ET AL: "Expression vector pET28a-LIC, complete sequence", 《GENBANK》 *
TOCHIO N 等: "ChainA，The Solution Structure of the Fifth Fibronectin Type III Domain of Human Neogenin. PDB: 1X5J_A", 《PDB数据库》 *
姚传义: "《数值分析》", 30 September 2009 *
张军英: "《说话人识别的现代方法与技术》", 31 October 1994 *
徐东: "《转录因子结合位点预测算法的研究与应用》", 31 December 2009 *
袁丽等: "用于筛选人工结合蛋白的骨架蛋白", 《中国生物工程杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112420124A (zh) * 2021-01-19 2021-02-26 腾讯科技（深圳）有限公司 一种数据处理方法、装置、计算机设备和存储介质
CN112420124B (zh) * 2021-01-19 2021-04-13 腾讯科技（深圳）有限公司 一种数据处理方法、装置、计算机设备和存储介质
WO2022156568A1 (zh) * 2021-01-19 2022-07-28 腾讯科技（深圳）有限公司 一种数据处理方法、装置、计算机设备和存储介质

Also Published As

Publication number Publication date
CN105143250B (zh) 2020-11-03
WO2014179983A1 (zh) 2014-11-13

Similar Documents

Publication Publication Date Title
JP6535361B2 (ja) 改変ノッチンペプチドを含む融合タンパク質及びその使用
Cavarelli et al. The active site of yeast aspartyl‐tRNA synthetase: structural and functional aspects of the aminoacylation reaction.
JP7217783B2 (ja) グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン
Meyer et al. Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals
Christie et al. Biogenesis, architecture, and function of bacterial type IV secretion systems
ES2414605T3 (es) Conjugados de ubiquitina o de gamma cristalinas para la utilización en la terapia, el diagnóstico y la cromatografía
Rich et al. Survey of the year 2003 commercial optical biosensor literature
CN103459415B (zh) 设计的与血清白蛋白结合的重复蛋白
Hughes et al. A highly specific monoclonal antibody against monkeypox virus detects the heparin binding domain of A27
EP2917388A1 (en) Nucleic acids encoding chimeric polypeptides for library screening
Lin et al. Analysis of capsid portal protein and terminase functional domains: interaction sites required for DNA packaging in bacteriophage T4
CN115461068A (zh) 仿生病毒肽的鉴定及其用途
JP2001510453A (ja) 相補的組み合わせライブラリーを使用する薬剤の同定
WO2020169838A1 (en) Modular binding proteins
Chen et al. Mapping multivalency in the CLIP-170–EB1 microtubule plus-end complex
CN105143250A (zh) 一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂
Okhrimenko et al. A survey of the year 2006 literature on applications of isothermal titration calorimetry
Collins et al. Structural dynamics of the membrane translocation domain of colicin E9 and its interaction with TolB
KR20130065215A (ko) 단백질 골격모듈을 포함하는 융합 폴리펩타이드 및 이를 이용한 목적 단백질에 특이적인 펩타이드 라이브러리 스크리닝 방법
Forsgren et al. Crystal structure of the variable domain of the Streptococcus gordonii surface protein SspB
US20080096229A1 (en) Modified Flagellins And Flagellar Filaments Useful As Receptors And Methods For The Preparation Thereof
WO2023203127A1 (en) Alphabody-based degrader molecules
Cross et al. A functional and structural comparative analysis of large tumor antigens reveals evolution of different importin α‐dependent nuclear localization signals
CN107209188A (zh) 用于检测人Pegivirus 2 (HPgV‑2)的组合物和方法
Hyun et al. Selection and syntheses of tentacle type peptides as ‘artificial’lectins against various cell-surface carbohydrates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant